Volume 104, Issue 11, Pages (November 2010)

Slides:

Advertisements

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

Advertisements

Biologics in Asthma—The Next Step Toward Personalized Treatment

Volume 100, Issue 2, Pages (February 2006)

Volume 100, Issue 10, Pages (October 2006)

Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment.

In vitro lymphocyte proliferation with milk and a casein–whey protein hydrolyzed formula in children with cow's milk allergy Philippe A. Eigenmann, MD,

Volume 144, Issue 2, Pages (August 2013)

Topiramate for the Treatment of Binge Eating Disorder Associated With Obesity: A Placebo-Controlled Study Susan L. McElroy, James I. Hudson, Julie A.

Volume 121, Issue 4, Pages (April 2002)

Martha Carvour, MD, PhD March 2, 2017

Individual gene expression and personalised medicine in sepsis

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients.

Suppression of Basophil FcεRI Activation by Serum from Active Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Subjects Patricia M. Sterba, Robert.

Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis Eva Gros, MSc, Susanne Petzold,

Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study Jean Luc Pouly, François Olivennes, Nathalie.

Effect of omalizumab in health care workers with occupational latex allergy Francisque Leynadier, MD, Ouafia Doudou, MD, Hafida Gaouar, MD, Vincent Le.

Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment.

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE- mediated hypersensitivity Oliver T. Burton, PhD, Stephanie L. Logsdon,

Frank Kirstein, PhD, Natalie E

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3) Aleena.

In vitro lymphocyte proliferation with milk and a casein–whey protein hydrolyzed formula in children with cow's milk allergy Philippe A. Eigenmann, MD,

Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis Kaori Mukai, PhD, Nicolas Gaudenzio,

Omalizumab treatment downregulates dendritic cell FcεRI expression

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment.

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut Leticia Tordesillas, PhD, Adeeb H. Rahman,

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,

Volume 152, Issue 6, Pages (December 2017)

Frank Kirstein, PhD, Natalie E

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season Alexander Kettner, PhD, Gilles DellaCorte, MD,

Direct monitoring of basophil degranulation by using avidin-based probes Régis Joulia, PhD, Claire Mailhol, MD, Salvatore Valitutti, MD, Alain Didier,

Volume 137, Issue 5, Pages (November 2009)

Expression of FcɛRI on dendritic cell subsets in peripheral blood of patients with atopic dermatitis and allergic asthma Inge M.J. Beeren, MSc, Marjolein.

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Volume 119, Issue 6, Pages (December 2000)

Volume 53, Issue 6, Pages (June 2008)

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients.

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations John H. Toogood, MD,

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Volume 75, Issue 12, Pages (June 2009)

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized,

Decreases in human dendritic cell–dependent TH2-like responses after acute in vivo IgE neutralization John T. Schroeder, PhD, Anja P. Bieneman, BS, Kristin.

Early decreases in blood eosinophil levels with reslizumab

Volume 23, Issue 4, Pages e3 (April 2018)

Basophil counts in PBMC populations during childhood acute wheeze/asthma are associated with future exacerbations Jonatan Leffler, PhD, Anya C. Jones,

Volume 75, Issue 12, Pages (June 2009)

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

John A. Eckman, MD, Patricia M

IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy Marc Humbert, MD, Jean Bousquet, MD, Claus Bachert, MD, Oscar.

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Sarbjit S. Saini, MDa, Jennifer J

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma Bob Lanier, MD, Tracy Bridges,

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis

Volume 68, Issue 3, Pages (September 2005)

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Impaired Interferon-Alpha Production by Plasmacytoid Dendritic Cells after Cord Blood Transplantation in Children: Implication for Post-transplantation.

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Perturbations of natural killer cell regulatory functions in respiratory allergic diseases Francesca Scordamaglia, MD, Mirna Balsamo, PhD, Antonio Scordamaglia,

Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis David W. Morris, MD, Emily M. Stucke, BA, Lisa.

Presentation transcript:

Volume 104, Issue 11, Pages 1608-1617 (November 2010) Omalizumab-induced decrease of FcɛRI expression in patients with severe allergic asthma Pascal Chanez, Cécile Contin-Bordes, Gilles Garcia, Christophe Verkindre, Alain Didier, Frédéric De Blay, Manuel Tunon de Lara, Patrick Blanco, Jean-François Moreau, Philip Robinson, Isabelle Bourdeix, Patrick Trunet, Vincent Le Gros, Marc Humbert, Mathieu Molimard Respiratory Medicine Volume 104, Issue 11, Pages 1608-1617 (November 2010) DOI: 10.1016/j.rmed.2010.07.011 Copyright © 2010 Terms and Conditions

Figure 1 Patient flow. All patients receiving one dose of study medication with at least one post-dose efficacy assessment were included in the Intent-To-Treat (ITT) population. The patients with missing pre- and/or post-treatment assessment(s) of FcɛRI expression were excluded from the ITT FcɛRI analyzable population for the primary endpoint. Abnormal laboratory result refers to serum IgE outside dosing table for omalizumab and abnormal test procedure refers to a technical issue with serum IgE determination. Respiratory Medicine 2010 104, 1608-1617DOI: (10.1016/j.rmed.2010.07.011) Copyright © 2010 Terms and Conditions

Figure 2 Change in FcɛRI expression on basophils and plasmacytoid dendritic cells (pDC2) at the end of study relative to baseline. The change in FcɛRI expression (mean fluorescence intensity, MFI) on (a) basophils and (b) pDC2 for individual patients in the omalizumab and placebo groups are shown. Median values are indicated by a solid bar to the right of each plot. Difference between median change found in omalizumab and placebo groups was statistically significant for (a) basophils p < 0.01 and (b) pDC2 p = 0.029. Respiratory Medicine 2010 104, 1608-1617DOI: (10.1016/j.rmed.2010.07.011) Copyright © 2010 Terms and Conditions

Figure 3 FcɛRI expression (MFI) on basophils in response to treatment in physician evaluated responders and non-responders (ITT FcɛRI analyzable population). Filled squares: omalizumab responders (n = 6), empty squares: omalizumab non-responders (n = 9), filled circles: placebo responders (n = 3), empty circles: non-responders (n = 6). Respiratory Medicine 2010 104, 1608-1617DOI: (10.1016/j.rmed.2010.07.011) Copyright © 2010 Terms and Conditions